Compare Cassava Sciences Inc (FLNA) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs TransMedics Group Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while TransMedics Group Inc trades at $77.43 (market cap $2.61B). The key difference: TransMedics Group Inc is far larger — about 49.1× Cassava Sciences Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | TMDX | |
|---|---|---|
Market Cap | $53.14M | $2.61B |
Sector | Health | Technology |
52-Week High | $4.64 | $150.42 |
52-Week Low | $1.09 | $61.99 |
Enterprise Value | -$33.43M | $3.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TransMedics (TMDX) trades at $77.46, up 3.85% on the day, with a bullish technical signal and strong analyst support. The company reported robust profitability with a 27.04% net margin and 45.22% ROE, though recent Q1 2026 earnings missed expectations. Strategic expansion into Europe via the PAD Aviation investment aims to strengthen its organ transplant logistics network, a key competitive advantage. The stock's valuation metrics include a P/E of 17.25 and P/S of 4.7.
The outlook remains positive with a $108.71 consensus price target (40% upside), supported by 9 buy ratings. Key opportunities include market share gains and European expansion, while risks involve margin pressure from investments and competitive threats. Execution on growth initiatives amid decelerating revenue growth will be critical for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
